A new treatment combining KEYTRUDA (pembrolizumab) with chemotherapy has been recommended by NICE for adults with advanced or recurrent womb cancer (endometrial cancer) who have not yet received treatment. This approval applies to patients with both mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR) tumours. Until now, immunotherapy with chemotherapy was only available for those with dMMR tumours. Endometrial cancer is the most common type of womb cancer and the most frequent gynaecological cancer in the UK, ranking as the fourth most common cancer in women, with over 9,700 new cases diagnosed each year. Most patients (around 70–75%) have pMMR tumours, which previously had fewer treatment choices. Clinical trial results showed that adding pembrolizumab to chemotherapy helped patients live longer without their cancer worsening compared to chemotherapy alone. Dr. Eleanor Jones from Peaches Womb Cancer Trust called this decision a positive step, especially for those with limited treatment options. Dr. Gemma Eminowicz, a cancer specialist, welcomed the new choice, particularly for pMMR patients who lacked immunotherapy options. Benson Fayehun from MSD UK also praised the decision, noting it provides an important alternative for patients in England and Wales.